Steven Spanhaak

FAQ About Steven Spanhaak

• What is Steven Spanhaak's address?

  Steven Spanhaak is located at
  Apeldoorn, Gelderland, Netherlands

• What is Steven Spanhaak's job title?

  Steven Spanhaak is a
  Apart from his specific background in the area of Immunotoxicology and significant expertise in preclinical compound development, over the years Steven developed the following additional occupations/passions:1)regulatory toxicology, i.e. especially supporting the improvement of the regulatory environment, and 2)preclinical safety data management, an essential link in support of safety assessment and innovation of preclinical safety testing. During his period at Janssen/J&J (2003-2021) he has been leading several activities related to: (1) improvement of the regulatory environment, (2) global impurity management, (3) nonclinical safety data management. He held several project management positions during his 13 years (1988-2000) at TNO, where he directed research in the area of Immunotoxicology/pharmacology and headed the immunotoxicity laboratory. Thereafter, expanding his toxicological expertise in the more general direction of drug development, he held a position as Safety Assessor and Global Preclinical Project Leader in the CNS and Immunology therapeutic areas at Organon. Steven joined J&J PRD, in 2003 as a Principal Scientist in the global preclinical development organization. During the years he gradually took on and substantially expanded a leadership role in the area of regulatory toxicology. From 2004 to 2018 he has been chairing the European Federation of Pharmaceutical Industries and Associations (EFPIA) Preclinical Development Expert Group. Under his leadership this group of senior preclinical safety experts, representing the various Pharma companies in Europe, was quite successful in their interactions with Regulatory Authorities resulting in the improvement of many guidelines. Steven was the EFPIA topic leader in the ICH expert working groups that drafted the recent ICH S8 (immunotoxicity), ICH M3 (timing of required nonclinical safety studies for the conduct of clinical trials), ICH S5 (developmental toxicity testing and the ICH M7 (genotoxic impurities) guidelines. Specialties: Immunotoxicology, Safety Assessment Pharmaceuticals, Regulatory Toxicology, Impurity Management, EFPIA, ICH D2team

• What industry does Steven Spanhaak currently work in?

  Steven Spanhaak currently works in the
  D2team

• What is Steven Spanhaak's area of expertise?

  Steven Spanhaak specializes in
  Apart from his specific background in the area of Immunotoxicology and significant expertise in preclinical compound development, over the years Steven developed the following additional occupations/passions:1)regulatory toxicology, i.e. especially supporting the improvement of the regulatory environment, and 2)preclinical safety data management, an essential link in support of safety assessment and innovation of preclinical safety testing. During his period at Janssen/J&J (2003-2021) he has been leading several activities related to: (1) improvement of the regulatory environment, (2) global impurity management, (3) nonclinical safety data management. He held several project management positions during his 13 years (1988-2000) at TNO, where he directed research in the area of Immunotoxicology/pharmacology and headed the immunotoxicity laboratory. Thereafter, expanding his toxicological expertise in the more general direction of drug development, he held a position as Safety Assessor and Global Preclinical Project Leader in the CNS and Immunology therapeutic areas at Organon. Steven joined J&J PRD, in 2003 as a Principal Scientist in the global preclinical development organization. During the years he gradually took on and substantially expanded a leadership role in the area of regulatory toxicology. From 2004 to 2018 he has been chairing the European Federation of Pharmaceutical Industries and Associations (EFPIA) Preclinical Development Expert Group. Under his leadership this group of senior preclinical safety experts, representing the various Pharma companies in Europe, was quite successful in their interactions with Regulatory Authorities resulting in the improvement of many guidelines. Steven was the EFPIA topic leader in the ICH expert working groups that drafted the recent ICH S8 (immunotoxicity), ICH M3 (timing of required nonclinical safety studies for the conduct of clinical trials), ICH S5 (developmental toxicity testing and the ICH M7 (genotoxic impurities) guidelines. Specialties: Immunotoxicology, Safety Assessment Pharmaceuticals, Regulatory Toxicology, Impurity Management, EFPIA, ICH

• Which languages does Steven Spanhaak speak? 

  Steven Spanhaak speaks the following languages:
  No languages available.

• Which industries has Steven Spanhaak previously worked in?   

  Steven Spanhaak has prior experience in the following industries:
  Johnson And Johnson , Efpia , Johnson And Johnson , Nv Organon , Tno Quality Of Life , Isala Klinieken

• What is Steven Spanhaak’s work experience?  

  Steven Spanhaak has the following professional experience:
  D2team , Spanhaak Consultancy Services , Johnson And Johnson , Efpia , Johnson And Johnson , Nv Organon , Tno Quality Of Life , Isala Klinieken .

• How can I find Steven Spanhaak on LinkedIn?  

  You can view Steven Spanhaak’s
  LinkedIn profile at LinkedIn URL.

• What are Steven Spanhaak’s work email addresses?  

  Steven Spanhaak’s work email addresses are
  [email protected] .

• What company does Steven Spanhaak work for?  

  Steven Spanhaak works at
  D2team